| # | Title | Journal | Year | Citations |
|---|
| 1 | Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer | New England Journal of Medicine | 2006 | 5,356 |
| 2 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Lancet, The | 2014 | 1,833 |
| 3 | Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,351 |
| 4 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,212 |
| 5 | Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Nature Genetics | 2014 | 1,103 |
| 6 | Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study | British Journal of Cancer | 2001 | 790 |
| 7 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2010 | 737 |
| 8 | Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study | Journal of the National Cancer Institute | 1998 | 671 |
| 9 | Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 663 |
| 10 | Genetic prognostic and predictive markers in colorectal cancer | Nature Reviews Cancer | 2009 | 602 |
| 11 | Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials | Antioxidants and Redox Signaling | 2008 | 573 |
| 12 | Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data | Journal of Clinical Oncology | 2004 | 455 |
| 13 | Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer | Journal of Clinical Oncology | 2006 | 432 |
| 14 | Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study | Lancet Oncology, The | 2007 | 416 |
| 15 | Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C) | Journal of Clinical Oncology | 2012 | 357 |
| 16 | A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia | Nature | 1987 | 356 |
| 17 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | Nature Genetics | 2017 | 356 |
| 18 | Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | British Journal of Cancer | 2000 | 336 |
| 19 | Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials | Cancer Treatment Reviews | 2003 | 334 |
| 20 | Radiation enteropathy—pathogenesis, treatment and prevention | Nature Reviews Gastroenterology and Hepatology | 2014 | 312 |
| 21 | Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial | Lancet Oncology, The | 2010 | 305 |
| 22 | Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial | Lancet Oncology, The | 2014 | 304 |
| 23 | Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients | Lancet Oncology, The | 2007 | 299 |
| 24 | Differential sensitivity of liposarcoma subtypes to chemotherapy | European Journal of Cancer | 2005 | 290 |
| 25 | Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation | Journal of Biological Chemistry | 2003 | 269 |
| 26 | Managing Patients Treated with Bevacizumab Combination Therapy | Oncology | 2005 | 265 |
| 27 | Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2013 | 250 |
| 28 | Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose | Journal of Clinical Oncology | 2007 | 225 |
| 29 | Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy | British Journal of Cancer | 2007 | 212 |
| 30 | Baseline quality of life predicts survival in patients with advanced colorectal cancer | European Journal of Cancer | 2002 | 210 |
| 31 | Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer | Lancet Oncology, The | 2007 | 199 |
| 32 | Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer | Journal of Clinical Oncology | 2003 | 197 |
| 33 | Gastrointestinal Problems after Pelvic Radiotherapy: the Past, the Present and the Future | Clinical Oncology | 2007 | 173 |
| 34 | Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up | European Journal of Surgical Oncology | 2014 | 162 |
| 35 | A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis | European Journal of Cancer | 2005 | 161 |
| 36 | International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI | Blood | 2020 | 158 |
| 37 | The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer | Journal of Clinical Oncology | 2004 | 153 |
| 38 | The role of mTOR in the management of solid tumors: An overview | Cancer Treatment Reviews | 2009 | 150 |
| 39 | Adjuvant therapy in colon cancer—what, when and how? | Annals of Oncology | 2006 | 142 |
| 40 | CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials | British Journal of Cancer | 2005 | 139 |
| 41 | Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer | British Journal of Cancer | 2005 | 137 |
| 42 | Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer | Annals of Oncology | 2005 | 136 |
| 43 | Part I: Chemotherapy for epithelial ovarian cancer–treatment at first diagnosis | Lancet Oncology, The | 2002 | 134 |
| 44 | Targeting the human EGFR family in esophagogastric cancer | Nature Reviews Clinical Oncology | 2011 | 132 |
| 45 | Part II: Chemotherapy for epithelial ovarian cancer-treatment of rcurrent disease | Lancet Oncology, The | 2002 | 131 |
| 46 | High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial | Lancet Haematology,the | 2016 | 128 |
| 47 | The views and practice of oncologists towards nutritional support in patients receiving chemotherapy | British Journal of Cancer | 2006 | 127 |
| 48 | Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine | Recent Patents on Anti-Cancer Drug Discovery | 2009 | 125 |
| 49 | The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induced emesis | European Journal of Cancer | 1993 | 123 |
| 50 | The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) | European Journal of Cancer | 2005 | 118 |
